Plus Therapeutics Future Growth
Future criteria checks 2/6
Plus Therapeutics is forecast to grow earnings and revenue by 7% and 63.9% per annum respectively while EPS is expected to grow by 26.6% per annum.
Key information
7.0%
Earnings growth rate
26.6%
EPS growth rate
| Biotechs earnings growth | 36.2% |
| Revenue growth rate | 63.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -43 | -61 | -60 | 3 |
| 12/31/2025 | 4 | -26 | -42 | -28 | 4 |
| 12/31/2024 | 5 | -14 | -14 | -12 | 4 |
| 6/30/2024 | 6 | -13 | -11 | -10 | N/A |
| 3/31/2024 | 6 | -12 | -12 | -12 | N/A |
| 12/31/2023 | 5 | -13 | -13 | -13 | N/A |
| 9/30/2023 | 4 | -15 | -13 | -13 | N/A |
| 6/30/2023 | 3 | -17 | -15 | -15 | N/A |
| 3/31/2023 | 1 | -21 | -15 | -15 | N/A |
| 12/31/2022 | 0 | -20 | -14 | -13 | N/A |
| 9/30/2022 | 0 | -19 | -14 | -13 | N/A |
| 6/30/2022 | N/A | -17 | -12 | -11 | N/A |
| 3/31/2022 | N/A | -15 | -12 | -11 | N/A |
| 12/31/2021 | N/A | -13 | -10 | -10 | N/A |
| 9/30/2021 | N/A | -13 | -11 | -11 | N/A |
| 6/30/2021 | N/A | -11 | -11 | -11 | N/A |
| 3/31/2021 | 0 | -10 | -11 | -10 | N/A |
| 12/31/2020 | 0 | -8 | -9 | -8 | N/A |
| 9/30/2020 | 1 | -4 | -5 | -4 | N/A |
| 6/30/2020 | 6 | -2 | -5 | -4 | N/A |
| 3/31/2020 | 6 | -2 | -4 | -4 | N/A |
| 12/31/2019 | 7 | -4 | -6 | -6 | N/A |
| 9/30/2019 | 7 | -7 | -9 | -9 | N/A |
| 6/30/2019 | 2 | -11 | -10 | -10 | N/A |
| 3/31/2019 | 2 | -9 | -11 | -11 | N/A |
| 12/31/2018 | 3 | -11 | -12 | -12 | N/A |
| 9/30/2018 | 4 | -18 | -14 | -14 | N/A |
| 6/30/2018 | 5 | -19 | -15 | -15 | N/A |
| 3/31/2018 | 6 | -24 | N/A | -17 | N/A |
| 12/31/2017 | 6 | -27 | N/A | -18 | N/A |
| 9/30/2017 | 8 | -23 | N/A | -18 | N/A |
| 6/30/2017 | 9 | -24 | N/A | -19 | N/A |
| 3/31/2017 | 10 | -24 | N/A | -19 | N/A |
| 12/31/2016 | 11 | -22 | N/A | -20 | N/A |
| 9/30/2016 | 12 | -20 | N/A | -20 | N/A |
| 6/30/2016 | 12 | -13 | N/A | -21 | N/A |
| 3/31/2016 | 12 | -2 | N/A | -20 | N/A |
| 12/31/2015 | 12 | -19 | N/A | -20 | N/A |
| 9/30/2015 | 12 | -24 | N/A | -21 | N/A |
| 6/30/2015 | 11 | -34 | N/A | -22 | N/A |
| 3/31/2015 | 9 | -51 | N/A | -26 | N/A |
| 12/31/2014 | 8 | -39 | N/A | -30 | N/A |
| 9/30/2014 | 7 | -42 | N/A | -35 | N/A |
| 6/30/2014 | 9 | -38 | N/A | -36 | N/A |
| 3/31/2014 | 10 | -29 | N/A | -34 | N/A |
| 12/31/2013 | 12 | -26 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XMP0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XMP0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XMP0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XMP0's revenue (63.9% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: XMP0's revenue (63.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XMP0's Return on Equity is forecast to be high in 3 years time